Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group
2013; Elsevier BV; Volume: 122; Issue: 4 Linguagem: Inglês
10.1182/blood-2013-01-480822
ISSN1528-0020
AutoresWanda L. Salzer, Barbara L. Asselin, Jeffrey G. Supko, Meenakshi Devidas, Nicole Kaiser, Paul V. Plourde, Naomi J. Winick, Gregory H. Reaman, Elizabeth A. Raetz, William L. Carroll, Stephen P. Hunger,
Tópico(s)Childhood Cancer Survivors' Quality of Life
ResumoKey Points Erwinia asparaginase was granted FDA approval in November 2011 for use in patients with allergic reactions to E coli-derived asparaginase. Erwinia asparaginase 25 000-IU/m2 for 6 intramuscular doses M/W/F can be substituted for a single dose of pegaspargase.
Referência(s)